Latest news with #MLOps
Time of India
27-05-2025
- Health
- Time of India
Royal Marsden, NTT DATA and CARPL.ai partner to launch AI-Powered Radiology service
London: The Royal Marsden NHS Foundation Trust has partnered with NTT DATA and to develop an AI-powered radiology analysis service aimed at advancing cancer research . The service will support the development and evaluation of artificial intelligence (AI) models in medical imaging, with the goal of improving diagnostic accuracy and patient outcomes . Funded by a three-year grant from the National Institute for Health and Care Research (NIHR), the service will be used in research at The Royal Marsden and the Institute of Cancer Research (ICR), including collaborative projects. Areas of focus include cancers such as sarcoma, lung, breast, brain, and prostate, with the aim of improving cancer evaluation and enabling more targeted treatments. The service runs on an MLOps clinical imaging system built and operated by NTT DATA. It includes high-performance Dell servers and GPU processing capabilities managed through which hosts a wide range of radiology AI models. NTT DATA is also providing consulting services to support testing and evaluation of emerging AI tools in real clinical settings. It is indicated that once the service becomes operational, research teams at The Royal Marsden will use it to assess a variety of AI models across different cancer types. The studies are expected to provide data on how AI tools may contribute to clinical decision-making and inform future diagnostic and treatment approaches. The service includes tools that allow researchers to observe model performance over time, helping to streamline the development and evaluation process. NTT DATA will continue its collaboration with The Royal Marsden to support ongoing research activities.
Business Upturn
27-05-2025
- Health
- Business Upturn
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
London, United Kingdom: This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation The Royal Marsden NHS Foundation Trust , a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA , a global leader in digital business and technology services, and , a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: 'Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. 'This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire
27-05-2025
- Business
- Business Wire
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
LONDON--(BUSINESS WIRE)-- The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. "This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.
Yahoo
23-05-2025
- Business
- Yahoo
Agentic AI, MLOps Platforms, and More
AI is set to revolutionize industries, transforming customer experience, operational efficiency, and IT operations. Key growth areas include Agentic AI, foundational models, MLOps, and responsible AI, enhancing scalability and ethical practices. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "AI: Top 10 Predictions, 2025" report has been added to offering. Artificial intelligence (AI) is emerging as a transformative megatrend with the potential to reshape industries of the future. AI is poised to drive unprecedented changes that redefine how businesses create and deliver value, including revolutionizing customer experience (CX), operational efficiency, and IT operations. Its profound impact on companies, economies, and societies makes it a pivotal technology in the digital landscape of an report highlights the top 10 growth opportunities in AI for 2025, spanning critical areas such as Agentic AI, foundational models, MLOps platforms, and responsible AI solutions. These advancements will not only enhance AI's scalability and efficiency but also reinforce ethical and transparent AI 2025, AI is expected to be integrated to a greater degree within enterprise applications and access to the technology will become more democratized. AI adoption is expected to remain robust, with enterprises continuing to build organizational readiness to compete in the new digital world and adopt best practices toward responsible AI. Top 10 Growth Opportunities for AI Agentic AI System Integration and Implementation Services AI Solutions and Application Software ICT Advisory Services Responsible AI Platforms and Services AI Data Lifecycle Management Services Foundational Models MLOps Platforms AI Training Data Center Infrastructure Services Edge AI Data Center Infrastructure For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
International Business Times
22-05-2025
- Health
- International Business Times
Building Trustworthy AI in Healthcare: Why Fairness and Accountability Are No Longer Optional
As artificial intelligence (AI) becomes increasingly embedded into clinical workflows, the healthcare industry is facing a new imperative not just to innovate, but to innovate ethically. From diagnosis and treatment recommendations to hospital resource allocation and insurance eligibility models, AI now plays a role in decisions that affect millions of lives. Yet as adoption rises, so too do concerns around bias, transparency, and regulatory compliance. One of the researchers leading the charge in solving this challenge is Vijaybhasker Pagidoju, a U.S.-based AI infrastructure specialist and healthcare systems engineer with extensive experience designing scalable, reliable, and audit-ready solutions for clinical settings. His recent research, "Fair and Accountable AI in Healthcare: Building Trustworthy Models for Decision-Making and Regulatory Compliance," sheds light on how AI systems can be both technically advanced and ethically responsible without compromising on performance. "Trust in healthcare AI isn't just a technical milestone it's a human requirement," says Vijaybhasker. "The goal is not only to make algorithms smarter, but to make their impact more equitable, explainable, and compliant." The Hidden Risks of "Black Box" AI in Medicine Despite the promise of AI-driven efficiencies in diagnostics and clinical support, many systems still operate as opaque "black boxes." These models may be highly accurate in aggregate, yet produce unequal outcomes across demographic groups a phenomenon that can lead to serious consequences in high-stakes environments like ICU triage or sepsis detection. Vijaybhasker's study evaluated real-world deployments of AI systems in hospitals across six countries, revealing performance disparities in predictive models when applied to women, publicly insured patients, and African American populations. "Bias was often invisible until broken down by race, gender, or insurance type," noted one ML engineer interviewed in the study. By integrating fairness-enhancing techniques such as Federated Learning with adversarial debiasing, the research demonstrated that it's possible to significantly improve fairness metrics (like Equal Opportunity Difference and Demographic Parity) without sacrificing accuracy. In one case, fairness gaps were reduced by over 80% with less than a 1% drop in predictive accuracy. Accountability Through Infrastructure and SRE Principles Beyond bias mitigation, the study makes a compelling case for embedding Site Reliability Engineering (SRE) and MLOps principles into the healthcare AI lifecycle a novel but increasingly necessary fusion. "AI systems need the same robustness, observability, and fault tolerance that we expect from mission-critical infrastructure," says Vijaybhasker, who brings years of real-world experience in AI-driven SRE for U.S. healthcare environments. His work outlines how practices like drift detection, incident logging, and real-time monitoring staples in modern SRE can be used not just to improve uptime, but to ensure regulatory traceability and ethical accountability. In fact, institutions that adopted such practices showed 40% faster response times to model failures, and were better prepared for external audits by organizations like the FDA and NHS. Clinical Trust Through Explainability A key insight from the study is that statistical fairness alone is not enough. Clinicians surveyed overwhelmingly said they were more likely to use and trust an AI system when they could understand how and why a decision was made. Tools like SHAP and LIME were integrated into dashboards, improving transparency and increasing clinician willingness to rely on AI by over 25%. This speaks to the growing importance of explainability not as an academic goal, but as a clinical necessity. When doctors are expected to justify treatment decisions, AI can't remain an untouchable black box. It must become an accountable partner. The Road Ahead: Ethical AI as Infrastructure The study concludes with a call for governance models, interdisciplinary collaboration, and continuous validation pipelines to be standard components of AI deployments in healthcare. Only 6 of the 15 institutions studied had formal AI ethics boards or compliance oversight processes in place yet those who did reported higher stakeholder trust and smoother regulatory outcomes. "Fair and accountable AI is not a one-time deliverable," Vijaybhasker emphasizes. "It's an infrastructure challenge a cultural, ethical, and operational shift." As AI continues to shape the future of healthcare, voices like his are setting the tone for what responsible innovation should look like. Trustworthy AI isn't just about better predictions; it's about building systems that doctors, patients, and regulators can count on every single time. Closing Thoughts Vijaybhasker Pagidoju's work stands out in a field increasingly defined by its complexity. By combining ethical AI design with principles of infrastructure reliability, his research provides a timely reminder that technology must ultimately serve people fairly, transparently, and accountably. As healthcare continues to evolve, voices like his are helping shape a more trustworthy future for intelligent systems.
